Literature DB >> 15471360

The 14-3-3 protein in multiple sclerosis: a marker of disease severity.

M Colucci1, L Roccatagliata, E Capello, E Narciso, N Latronico, M Tabaton, G L Mancardi.   

Abstract

CONTEXT: In multiple sclerosis (MS) axonal damage is an early event and is probably to be considered the most relevant cause of permanent and progressive disability.
OBJECTIVES: To investigate the value of the increase of 14-3-3 and tau proteins in the cerebrospinal fluid (CSF) as peripheral markers of axonal pathology and predictors of disease evolution. PATIENTS AND METHODS: In the CSF samples obtained from 63 patients with demyelinating diseases (DD), including 20 clinically isolated syndromes (CIS) and 43 clinically defined MS, as well as from 56 controls, we analysed the presence of 14-3-3 reactivity by immunoblot analysis along with the concentration of tau protein by sandwich ELISA.
RESULTS: The percentage of DD subjects showing a positive 14-3-3 protein CSF reactivity (38%) was significantly higher than the one previously detected, and was correlated in the MS patients with a more severe clinical phenotype in terms of degree of disability and rate of disease progression, during a 10-month mean clinical follow-up. On the contrary, the levels of the CSF-tau protein were highly variable in DD and control subjects, and the mean CSF-tau concentration was similar in both groups.
CONCLUSIONS: The immunoblot analysis of 14-3-3 protein in the CSF could be a useful marker to identify a subgroup of DD patients with high risk of developing severe disability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471360     DOI: 10.1191/1352458504ms1089oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  18 in total

1.  The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis.

Authors:  H Bartosik-Psujek; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

Review 2.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 3.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

4.  [Proportion of tau protein to phosphorylated tau protein CSF levels in differential diagnosis of dementia].

Authors:  J Hort; M Valis; G Waberzinek; R Taláb; L Glossová; M Bojar; M Vyhnálek; D Skoda; J Masopust; P Stourac
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

5.  Suppression of the Peripheral Immune System Limits the Central Immune Response Following Cuprizone-Feeding: Relevance to Modelling Multiple Sclerosis.

Authors:  Monokesh K Sen; Mohammed S M Almuslehi; Erika Gyengesi; Simon J Myers; Peter J Shortland; David A Mahns; Jens R Coorssen
Journal:  Cells       Date:  2019-10-24       Impact factor: 6.600

6.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02

Review 7.  Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?

Authors:  Alberto Gajofatto; Matilde Bongianni; Gianluigi Zanusso; Maria Donata Benedetti; Salvatore Monaco
Journal:  Int J Mol Sci       Date:  2011-11-16       Impact factor: 5.923

8.  Proteomic analysis of human cerebral endothelial cells activated by multiple sclerosis serum and IFNbeta-1b.

Authors:  J Steven Alexander; Alireza Minagar; Michael Harper; Sherry Robinson-Jackson; Merilyn Jennings; Stacy J Smith
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

9.  Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study.

Authors:  Alireza Minagar; Irena Adamashvili; Roger E Kelley; Eduardo Gonzalez-Toledo; Jerry McLarty; Stacy J Smith
Journal:  J Neuroinflammation       Date:  2007-07-01       Impact factor: 8.322

Review 10.  Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?

Authors:  Ahmed Abdelhak; Andreas Junker; Johannes Brettschneider; Jan Kassubek; Albert C Ludolph; Markus Otto; Hayrettin Tumani
Journal:  Int J Mol Sci       Date:  2015-07-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.